SCHEMBL1156068

SCHEMBL1156068

CC(C)OS(=O)(=O)c1ccc2[nH]c(C(N)=O)cc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 3/20 0.42
MMP2 P08253 2/20 0.42
CFD P00746 1/20 0.41
KDM4E B2RXH2 4/20 0.41
LMNA P02545 2/20 0.41
TP53 P04637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
PDGFRB P09619 3/20 0.40
PDGFRA P16234 2/20 0.40
PIN1 Q13526 1/20 0.38
XDH P47989 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 2/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
FLT3 P36888 3/20 0.37
ABL1 P00519 1/20 0.37
KIT P10721 1/20 0.37
BCR P11274 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12863073 0.88 KDM4E (0.42) MMP13MMP2KDM4ELMNATP53
SCHEMBL1156429 0.88 PIN1 (0.52) MMP13MMP2KDM4ELMNATP53
SCHEMBL1156048 0.83 TRPM8 (0.45) MMP13MMP2KDM4ELMNATP53
SCHEMBL3283474 0.80 MMP2 (0.45) MMP13MMP2CFDKDM4ELMNA
SCHEMBL8277072 0.79 PIN1 (0.51) MMP13MMP2KDM4ELMNATP53
SCHEMBL8277574 0.79 CA2 (0.47) MMP13MMP2CFDKDM4ELMNA
SCHEMBL1159769 0.79 PDGFRB (0.44) MMP13MMP2CFDKDM4ELMNA
SCHEMBL1156492 0.72 CA12 (0.48) RAB9AMAPTF7F3
SCHEMBL11960184 0.70 PIN1 (0.72) MMP13MMP2KDM4ETP53PDGFRB
SCHEMBL1616290 0.70 MMP13 (0.47) MMP13MMP2CFDKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776106-B1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMA (US) 2013-08-07 EP disclosed
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed
US-20060074076-A1 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C MMP13 4513/4885MMP2 4551/4885CFD 3888/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C MMP13 4513/4885MMP2 4551/4885CFD 3888/4885
US-20060074076-A1 Heterocyclic derivatives for modulation of calcium channels CACNA1D, ORAI1, CACNA1C MMP13 4513/4885MMP2 4551/4885CFD 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.